Aditxt, Inc. (ADTX)

NASDAQ: ADTX · IEX Real-Time Price · USD
3.40
-0.57 (-14.36%)
At close: Dec 1, 2023, 4:00 PM
3.36
-0.04 (-1.18%)
After-hours: Dec 1, 2023, 7:59 PM EST
-14.36%
Market Cap 1.50M
Revenue (ttm) 749,475
Net Income (ttm) -29.73M
Shares Out 441.85K
EPS (ttm) -13.17
PE Ratio n/a
Forward PE 0.37
Dividend n/a
Ex-Dividend Date n/a
Volume 551,102
Open 3.62
Previous Close 3.97
Day's Range 3.30 - 3.94
52-Week Range 3.27 - 76.40
Beta 1.13
Analysts Strong Buy
Price Target 61.00 (+1,694.12%)
Earnings Date Nov 14, 2023

About ADTX

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ trans... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2020
Employees 61
Stock Exchange NASDAQ
Ticker Symbol ADTX
Full Company Profile

Financial Performance

In 2022, Aditxt's revenue was $933,715, an increase of 788.96% compared to the previous year's $105,034. Losses were -$27.61 million, -40.32% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ADTX stock is "Strong Buy" and the 12-month stock price forecast is $61.0.

Price Target
$61.0
(1,694.12% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aditxt, Inc. to Present at 8th Annual Dawson James Conference

Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2...

2 months ago - GlobeNewsWire

Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of techno...

2 months ago - Business Wire

Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

RICHMOND, Va. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing ...

3 months ago - Business Wire

Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...

3 months ago - Business Wire

Aditxt stock price has plummeted: avoid at all cost

Aditxt (NASDAQ: ADTX) stock price has been in the spotlight in the past few days. The shares plunged by more than 24% on Friday, one of its worst days this year.

3 months ago - Invezz

Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the...

3 months ago - Business Wire

Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale

RICHMOND, Va.--(BUSINESS WIRE)-- #autoimmunity--Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therape...

3 months ago - Business Wire

CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

RICHMOND, Va.--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and ...

3 months ago - Business Wire

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system...

3 months ago - Business Wire

Aditxt, Inc.'s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics

RICHMOND, Va.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate...

5 months ago - Business Wire

Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome

RICHMOND, Va.--(BUSINESS WIRE)-- #StiffPersonSyndrome--Aditxt®, Inc. announces that its subsidiary Adimune,™ Inc. has signed a clinical trial agreement with Mayo Clinic to study Stiff Person Syndrome.

7 months ago - Business Wire

Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...

7 months ago - Business Wire

Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the...

8 months ago - Business Wire

Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune syst...

8 months ago - Business Wire

Aditxt Issues Shareholder Update

RICHMOND, Va--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate ...

8 months ago - Business Wire

Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...

9 months ago - Business Wire

Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...

9 months ago - Business Wire

Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...

10 months ago - Business Wire

Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modul...

11 months ago - Business Wire

FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc.'s (NASDAQ: ADTX) (“Aditxt”, or the “Company”) AditxtScore™ is featured by FedEx in a video presentation that showcases the various ways in which both compa...

1 year ago - Business Wire

Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulat...

1 year ago - Business Wire

Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating t...

1 year ago - Business Wire

Aditxt Announces Closing of $20.0 Million Public Offering

RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (Nasdaq: ADTX) (the “Company” or “Aditxt”), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating ...

1 year ago - Business Wire